All In Biotech

Drug Trial Radar · NCT07742280

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Brexpiprazole for Extended-Release Injection in Subjects With Schizophrenia

An Open-Label, Multi-Center Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Brexpiprazole for Extended-Release Injection Administered as a Single Dose in Subjects With Schizophrenia

Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

16

Planned (sponsor's estimate)

Start

Aug 2026

Primary completion

Aug 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Bostal Drug Delivery Co., LtdIndustry
Sponsor type
Industry
First posted
Aug 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the pharmacokinetics (PK), safety and tolerability of Brexpiprazole, administered subcutaneously, in subjects with schizophrenia.

Conditions

  • Schizophrenia

Interventions

  • Brexpiprazole for ER injection, 45 mgDrug

    Single-dose, Subcutaneous

  • Brexpiprazole for ER injection, 100 mgDrug

    Single-dose, Subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: Pre-dose to 190 days post-dose
  2. ClastTime frame: Pre-dose to 190 days post-dose
  3. TmaxTime frame: Pre-dose to 190 days post-dose
  4. AUC0-lastTime frame: Pre-dose to 190 days post-dose
  5. KelTime frame: Pre-dose to 190 days post-dose
  6. T1/2Time frame: Pre-dose to 190 days post-dose
  7. Vd/FTime frame: Pre-dose to 190 days post-dose
  8. CL/FTime frame: Pre-dose to 190 days post-dose
  9. MRTTime frame: Pre-dose to 190 days post-dose
  10. AUC_%Extrap_obsTime frame: Pre-dose to 190 days post-dose
  11. AEsTime frame: Day 1 to Day 190
  12. SAEsTime frame: Day 1 to Day 190
  13. Change from baseline in physical examination findingsTime frame: Day 1 to Day 190
  14. Blood PressureTime frame: Day 1 to Day 190
  15. Orthostatic hypotensionTime frame: Day 1 to Day 190
  16. Columbia-Suicide Severity Rating Scale (C-SSRS) assessmentTime frame: Day 1 to Day 190
  17. Clinical Laboratory TestsTime frame: Day 1 to Day 190
  18. 12-lead ECG AssessmentTime frame: Day 1 to Day 190
  19. Pulse RateTime frame: Day 1 to Day 190
  20. Respiratory RateTime frame: Day 1 to Day 190
  21. Body TemperatureTime frame: Day 1 to Day 190

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.